274 related articles for article (PubMed ID: 15013941)
1. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?
Pershadsingh HA
Expert Opin Investig Drugs; 2004 Mar; 13(3):215-28. PubMed ID: 15013941
[TBL] [Abstract][Full Text] [Related]
2. Modulation of PPARgamma activity with pharmaceutical agents: treatment of insulin resistance and atherosclerosis.
Wang M; Tafuri S
J Cell Biochem; 2003 May; 89(1):38-47. PubMed ID: 12682906
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator activator receptors (PPAR), insulin resistance, and cardiomyopathy: friends or foes for the diabetic patient with heart failure?
Nikolaidis LA; Levine TB
Cardiol Rev; 2004; 12(3):158-70. PubMed ID: 15078585
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and additional vascular effects of thiazolidinediones.
Martens FM; Visseren FL; Lemay J; de Koning EJ; Rabelink TJ
Drugs; 2002; 62(10):1463-80. PubMed ID: 12093315
[TBL] [Abstract][Full Text] [Related]
5. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
6. [Rosiglitazone(BRL-49653)].
Yonezawa N; Oka Y
Nihon Rinsho; 2001 Nov; 59(11):2195-9. PubMed ID: 11712407
[TBL] [Abstract][Full Text] [Related]
7. A novel method for analysis of nuclear receptor function at natural promoters: peroxisome proliferator-activated receptor gamma agonist actions on aP2 gene expression detected using branched DNA messenger RNA quantitation.
Burris TP; Pelton PD; Zhou L; Osborne MC; Cryan E; Demarest KT
Mol Endocrinol; 1999 Mar; 13(3):410-7. PubMed ID: 10076998
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
9. [Thiazolidinediones in type 2 diabetes. Role of peroxisome proliferator-activated receptor gamma (PPARgamma)].
Dubois M; Vantyghem MC; Schoonjans K; Pattou F
Ann Endocrinol (Paris); 2002 Dec; 63(6 Pt 1):511-23. PubMed ID: 12527853
[TBL] [Abstract][Full Text] [Related]
10. Experimental approaches to study PPAR gamma agonists as antidiabetic drugs.
Vázquez M; Silvestre JS; Prous JR
Methods Find Exp Clin Pharmacol; 2002 Oct; 24(8):515-23. PubMed ID: 12500431
[TBL] [Abstract][Full Text] [Related]
11. A novel peroxisome proliferator-activated gamma (PPAR gamma) agonist, CLX-0921, has potent antihyperglycemic activity with low adipogenic potential.
Dey D; Medicherla S; Neogi P; Gowri M; Cheng J; Gross C; Sharma SD; Reaven GM; Nag B
Metabolism; 2003 Aug; 52(8):1012-8. PubMed ID: 12898466
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.
Koh EH; Kim MS; Park JY; Kim HS; Youn JY; Park HS; Youn JH; Lee KU
Diabetes; 2003 Sep; 52(9):2331-7. PubMed ID: 12941773
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival.
Wang YL; Frauwirth KA; Rangwala SM; Lazar MA; Thompson CB
J Biol Chem; 2002 Aug; 277(35):31781-8. PubMed ID: 12082115
[TBL] [Abstract][Full Text] [Related]
14. Cardioprotective effects of thiazolidinediones, peroxisome proliferator-activated receptor-gamma agonists.
Yue TL
Drugs Today (Barc); 2003 Dec; 39(12):949-60. PubMed ID: 14747840
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones, peroxisome proliferator-activated receptor gamma agonists, regulate endothelial cell growth and secretion of vasoactive peptides.
Fukunaga Y; Itoh H; Doi K; Tanaka T; Yamashita J; Chun TH; Inoue M; Masatsugu K; Sawada N; Saito T; Hosoda K; Kook H; Ueda M; Nakao K
Atherosclerosis; 2001 Sep; 158(1):113-9. PubMed ID: 11500181
[TBL] [Abstract][Full Text] [Related]
16. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer.
Murphy GJ; Holder JC
Trends Pharmacol Sci; 2000 Dec; 21(12):469-74. PubMed ID: 11121836
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic actions of PPAR gamma activators thiazolidinediones in cardiovascular diseases.
Takano H; Hasegawa H; Zou Y; Komuro I
Curr Pharm Des; 2004; 10(22):2779-86. PubMed ID: 15320743
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of rexinoids and thiazolidinediones on metabolic gene expression in diabetic rodents.
Singh Ahuja H; Liu S; Crombie DL; Boehm M; Leibowitz MD; Heyman RA; Depre C; Nagy L; Tontonoz P; Davies PJ
Mol Pharmacol; 2001 Apr; 59(4):765-73. PubMed ID: 11259621
[TBL] [Abstract][Full Text] [Related]
19. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
